Emergent Biosolutions’ (EBS) “Buy” Rating Reaffirmed at HC Wainwright

Emergent Biosolutions (NYSE:EBS)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 66.53% from the company’s previous close.

Several other brokerages have also commented on EBS. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a research report on Tuesday, August 11th. Benchmark restated a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. UBS Group reiterated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a report on Friday, August 21st. They issued an “underweight” rating for the company. Finally, Weiss Ratings raised Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, August 21st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Emergent Biosolutions presently has a consensus rating of “Hold” and an average price target of $10.00.

Emergent Biosolutions Trading Down 3.3%

Shares of NYSE:EBS opened at $6.00 on Wednesday. Emergent Biosolutions has a 12-month low of $4.36 and a 12-month high of $14.06. The company has a quick ratio of 2.95, a current ratio of 5.42 and a debt-to-equity ratio of 1.70. The firm has a fifty day moving average of $6.60 and a two-hundred day moving average of $7.83. The firm has a market capitalization of $307.88 million, a P/E ratio of -1.69 and a beta of 2.34.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%.The business had revenue of $234.30 million for the quarter, compared to analyst estimates of $177.50 million. On average, equities analysts expect that Emergent Biosolutions will post 0.13 EPS for the current fiscal year.

Insider Transactions at Emergent Biosolutions

In other news, SVP Paul Williams sold 3,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the completion of the transaction, the senior vice president owned 159,098 shares of the company’s stock, valued at approximately $1,336,423.20. This represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC bought a new stake in shares of Emergent Biosolutions in the second quarter valued at approximately $29,000. Legal & General Group Plc purchased a new position in Emergent Biosolutions during the second quarter worth about $31,000. Public Employees Retirement System of Ohio bought a new stake in shares of Emergent Biosolutions in the second quarter valued at $36,000. CANADA LIFE ASSURANCE Co purchased a new position in Emergent Biosolutions during the fourth quarter valued at approximately $45,000. Finally, California State Teachers Retirement System increased its stake in Emergent Biosolutions by 112.8% in the second quarter. California State Teachers Retirement System now owns 6,008 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 3,185 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.